{4-[(2s,4e)-2-(1,3-benzothiazol-2-yl)-2-(1h-1,2,3-benzotriazol-1-yl)-5-phenylpent-4-enyl]phenyl}(difluoro)methylphosphonic acid

This compound is a synthetic small molecule with the chemical formula C31H25F2N4O3PS and a molecular weight of approximately 602.6 g/mol[1][3]. It is also known by the code names P90 and DB04285. The molecule contains benzothiazole and benzotriazole moieties linked via a pentenyl chain to a difluoromethylphosphonic acid group. It has been identified as an experimental compound in drug databases but is not approved for clinical use[3][7]. Computational studies have suggested that it may act as an inhibitor of the SARS-CoV‐2 main protease (also known as 3CLpro), which plays a critical role in viral replication; thus it has been proposed as a potential antiviral agent against COVID‐19 based on molecular docking and simulation data[6]. However, there are no reported clinical trials or approved indications for this compound.

Other names

((4-((2R,4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-1,2,3-benzotriazol-1-yl)-5-phenylpent-4-en-1‑yl)phenyl)difluoromethyl)phosphonic acid({4‑[(2R,4E)‑2‑(1,3‑benzothiazol‑2‑yl)‑2‑(1H–1, 23–benzotriazol– 11– yl ) –5 – phen ylpent – 44 – en – 11 ‑ yl ] phen yl } difluoromethyl ) phosphonic acid